Context: Synthetic cannabinoids (SCs) such as "Spice", "K2" etc. are widely available via the internet despite increasing legal restrictions. Currently, the prevalence of use is typically low in the general community (<1%) although it is higher among students and some niche groups subject to drug testing. Early evidence suggests that adverse outcomes associated with the use of SCs may be more prevalent and severe than those arising from cannabis consumption.
Introduction
Synthetic cannabinoids (SCs) first appeared in the 1960s in research laboratories exploring potential medical uses targeting cannabinoid receptors. 1 At the end of the first decade of this century, SCs reappeared through internet marketing of so-called "legal highs". The best-known common names are "Spice" and "K2". 1, 2 Although these products typically contain a variety of plant materials, most of the species reported are not believed to have psychoactive properties, with the primary active ingredients being synthetic cannabinoid (SC) receptor agonists sprayed onto the base material. 1 The HU series (developed at the Hebrew University) the CP series (from Pfizer Inc.) and the JWH series (developed by JW Huffman) are the major groups of SCs. 3 These drugs can have a greater potency and binding affinity than Δ 9 -tetrahydrocannabinol (Δ 9 THC) the main intoxicant in traditional cannabis products that they mimic. 2, 3 Further, as potentially full agonists at the cannabinoid receptor (CB 1 ), compared with the partial agonist properties of Δ 9 THC, there is likely to be an increased risk of major psychiatric complications and other adverse effects. 1, 2 Other serious side effects, particularly sympathomimetic and hallucinogenic effects related to new compounds may be due to indirect activation of other receptors via excess activation of cannabinoids receptors, direct receptor activations due to mixed receptor effects of new cannabinoids, or possibly adulterants including plant material effects. 2 Winstock and colleagues estimated that the risk of requiring emergency medical treatment is between 14 and 30 times greater following the use of synthetic compared with traditional cannabis 4 , with an online survey of SC users reporting that 2.5% had sought emergency treatment in the past 12 months. 5 Data from population surveys suggest that recent use (i.e. last year) of 'Spice' like products is low, for example 0.2% in England and Wales 6 and 0.4% in Germany. 7 However, 2013 survey data from Australia suggests increasing rates of use with 1.2% of the population reporting use within one year and 2.5% in those under 25 years. 8 However, prevalence may be markedly higher in some subpopulations. Heltsley et al, analysed urine samples from athletes who were subject to routine screening for performance enhancing and illicit drugs and found 4.5% were using synthetic cannabis, presumably assuming that, at the time, there was a low probability of detection. 9 A survey of 852 college students in Florida reported that 8% had ever used SC 10 and the American Monitoring the Future study reported an annual prevalence of 11.4% in 12 th grade students (age 17-18 years), second only to cannabis use. 11 Vandrey et al found that about 30% of SC users include the avoidance of drug testing among their reasons for using SCs, although though this figure may be higher in the United States due to the widespread testing of employees in some sectors (e.g.
transportation, Federal agencies). 12, 13 Data collection specific to emergency department (ED) presentations involving SCs began with the US National Forensic Laboratory Information System detecting 23 SC cases in 2009. By 2012, this number had grown to over 41,000 cases. 14 Similarly, the US Drug Abuse Warning Network (DAWN) recorded over 11,000 cases in 2010 and over 28,000 in 2011. 15 Similar dramatic increases have also occurred in Europe. In the UK, there was a seven fold increase in enquires to TOXBASE between 2011/12 and 2012/13 by healthcare workers in relation to poisoning presentations involving SC. 16 Nevertheless, many emergency physicians are unfamiliar with SCs and feel unprepared to care for intoxicated users. 17 The analysis of the chemical constituents of 'Spice' shows that the quantity and type of SCs varies widely, with some products containing no active compounds or other active non-cannabinoid substances such as the synthetic opioid O-desmethyltramadol. 18 Chronological analysis suggests that the SCs in commercial products may have changed in response to legislative restrictions: for example, JWH-073 appeared in Germany only after JWH-018 was controlled. 18 Thus, consumers are unlikely to be able to gauge the potential effects or risks of particular products as the constituents change over time. The method of preparation of these products further adds to the potential hazards associated with them. Production typically involves spraying chemical compounds dissolved in acetone onto a plant base. The resulting products may vary in the composition, concentration, and distribution of SCs within a batch and among batches of similar products. A further complication for medical staff assessing presentations thought to involve SCs is the lack of a simple urine or blood-screening test to confirm its presence.
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A recent paper on SCs adopted a comprehensive approach to examining the clinical implications arising from research into SCs, their epidemiology, receptor interactions, and human and animal pharmacodynamics. 20 The objective of this review is a more focused approach to identify the typical signs and symptoms of exposure to SCs and particular idiosyncratic presentations involving
SCs from hospital presentations and poison centre data. We also aimed to summarize interventions or treatment provided in the hospital management of these cases when these data were available.
Method
In December 2014, we systematically searched Medline, PsycInfo, Embase, Google Scholar and Pubmed for reports. In brief the strategy was (emergency department OR hospital OR Poison Control Centers OR substance related disorders OR Drug Overdose) AND (Synthetic cannabis OR synthetic cannabinoid). Online data supplement 1 contains an example of the syntax (for the Ovid Medline search). Given the nascent state of the literature, we also backward searched the references of retrieved papers to identify early material such as conference presentations.
Inclusion criteria
The target substance was any SC (e.g. "Spice", "K2" etc.). Adverse events had to be recorded by medical staff e.g. at hospitals, drug rehabilitation services, or emergency facilities as opposed to self-reporting via surveys. The exception to this were Poison Centre reports that collect data from a variety of sources, including the public, but are coded by specialists in poisons information, including nurses, pharmacists, or scientists. 21 Both self-reported and analytically confirmed use of SCs were eligible for inclusion, as were presentations involving SCs plus other drugs.
Results
We identified 323 records from the database search. We supplemented these with 41 from hand searching references (see Figure 1 , PRISMA diagram). After we had excluded duplicates and had screened titles, we reviewed 136 full texts: we subsequently excluded 30 (Online data 2). Overall, 106 papers, letters and conference abstracts were eligible for inclusion in the study, representing over 4000 cases. The tables have been arbitrarily sub-divided into case series (defined as > 10 cases) and case studies (<10 cases) on the expectation that the former will provide the more reliable evidence on the typical symptoms while the latter will have more detail on interventions and highlight the most unusual presentations. We identified 14 case series and 55 case reports from journals (Tables 1 and 2 ) plus a further 15 case series and 22 case reports from conference abstracts (online data 3).
Poison Centre data, including nearly 1900 cases from the USA National Poison Data System for nine months in 2010, represented the largest samples. 22 The prototypical presentation is a young male (59-100%) with tachycardia (37-77%), agitation (16-41%) and nausea (13-94%) (see Table 1 ).
Most cases received observation and supportive care (intravenous fluids, benzodiazepines, oxygen) and left emergency within eight hours. Nevertheless, some cases and series presented with more severe conditions. These cases typically do not include analytically confirmed exposure to SC.
Mortality
There have been both case series and case reports of deaths associated with the use of SC. Shanks and colleagues report on SC concentrations from samples collected during 18 autopsies, although the focus of the paper was primarily a methodological description of the analysis of JWH-018 and -073 from post-mortem whole blood. 23 The same team reported on a further four deaths involving 5F-PB-22, with sudden cardiac dysrhythmias or seizures suggested as a potential mechanism in three of the cases, whilst, in the fourth, liver and kidney failure was noted. 24 23, 24 may include deaths reported in other USA case studies. Thus, a conservative estimate of the number of reported SC deaths is 22 (maximum 27) in the USA, three from Europe and one in Japan.
Cardiovascular
Tachycardia is the most prevalent clinical effect reported in the literature. Poison Centres frequently record this effect in association with hypertension as symptoms of SC presentations, with tachycardia occurring in 1/3 to 3/4 of presentations. [31] [32] [33] In some cases, there are also reports of chest pain. [34] [35] [36] In addition, there are case reports of more severe outcomes including perimesencephalic subarachnoid haemorrhage 37 , middle cerebral artery occlusion [38] [39] [40] [41] and three cases of myocardial infarction in adolescent males. 42 Ibrahim and colleagues also report a cardiac arrest in a 56 year-old man with an earlier four-vessel bypass graft. 43 
Acute kidney injury (AKI)
Poison Centre data show that queries on renal problems account for less than 1% of SC calls 44 but various reports describe acute kidney injury (AKI) in the setting of acute SC toxicity. The Centers for Disease Control (CDC) identified 16 AKI cases over nine months, typically presenting as nausea, vomiting and flank pain with associated elevated peak serum creatinine (range 3.3-21.0 mg/dl). SCs exposure was analytically confirmed in six of seven cases tested (XLR-11, UR-144, indole precursor). There was also evidence of elevated white blood cell count, proteinuria and haematuria. Renal biopsies in a series of eight patients found acute tubular injury (five patients), acute interstitial nephritis (two patients) or both (one person). 45 An additional four AKI cases were reported from Alabama in otherwise healthy young men 46 and nine in Oregon (including five previously recorded by the CDC). 45 All required hospitalization for up to eight days. 47 
Generalized tonic-clonic seizure (GTC)
The Hoyte review found 52 (3.8%) poison centre reports on SCs included GTC seizures with two cases of status epilepticus (SC unknown). 22 However, in a CDC case series of emergency department SC presentations, 14% involved GTC seizures 48 and a review of paediatric (0-19 years)
poison centre reports found that 15% involved seizures. 49 Seizures are also prominent in the case report literature, including those with analytically confirmed SC exposure (e.g. JWH-122, -210, -018: PB-22: BB-22, AM-2233, PB-22, 5F-PB-22, JWH-122).
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Gastrointestinal Nausea and vomiting are often conspicuous features of SC presentations (e.g. 
Psychiatric presentations
As noted in the Tables 1 and 2 , many presentations include behavioural features such as agitation.
However, more severe psychiatric presentations are also prevalent. Hurst et al reported on 10 cases of new onset psychosis associated with SC use from San Diego, although only two involved just the use of SCs, with the remainder consuming cannabis or alcohol either concurrently or in the recent past. 58 Hospitalization lasted between 6-10 days and in one case, symptoms persisted for more than five months. An audit of an open adult ward in New Zealand found 13% (n=17) of psychiatric admissions were probably related to SC consumption, including four first time admissions (affective, suicidal or psychotic symptoms) plus four first admissions with psychosis. 59 New onset psychosis has also been reported by others [60] [61] [62] [63] [64] including with significant self-injury 65 , catatonic features 66 and Capgras delusion. 67 SC use has also been described as exacerbating symptoms in those receiving psychiatric treatment 68 , initiating drug induced psychosis (with no known history of drug-induced psychosis), 69 and precipitating a recurrence of cannabis induced psychosis.
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SC presentations also include symptoms of panic attack 51, 71 , anxiety, paranoia and hallucinations. 72, 73 Two case reports have described withdrawal symptoms following the cessation of SCs 74, 75 similar to those associated with cannabis withdrawal.
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Discussion
The prevalence of synthetic cannabinoid (SC) consumption is low in the general population. [6] [7] [8] However, the risk of requiring medical attention following use of SC seems to be greater than that for cannabis consumption. 4 Our systematic review of adverse events found that typically events
were not severe, only required symptomatic or supportive care and were of short duration.
Nevertheless, a number of deaths have been attributed either directly or indirectly to SC consumption, together with other major adverse sequelae, including a significant number with persistent effects including new on-set psychosis with no family history of psychosis. 58 We did not include popular media reports or the grey literature in the search, which would probably reveal further cases but would be less likely to contain reliable medical information. We were unable to determine the exact number of cases in the scientific literature due to the potential overlap between poison centre data and hospital reports. We could not even definitively established the number of deaths attributed to SC consumption. Of the 28,531 ED visits in 2011 recorded in the DAWN database, 119 (0.4%) led to death potentially related to SC use. 77 Our review of published cases identified only 22 fatal cases in the US through the end of 2014. As not all presentations especially for psychiatric problems or palpitations will include assessment of SC use, SC presentations may currently be seriously underreported. This suggests that the magnitude of the health burden due to SC use is considerably greater than that currently documented. Most of the data were based on self-reported consumption of SC, with no simple screening test available yet for clinicians.
Some of the information on adverse effects of SCs arises from poison center data. Wood et al outlined the strengths and weakness of poison center data for novel psychoactive substances. 21 In brief, poison centers may detect new and unfamiliar exposures, but the rates of detection may decline with familiarity with the substances involved. In addition, the data depend upon voluntary reporting, often lack analytical confirmation, and may not discern which symptoms to attribute to a given substance, in cases of poly-drug exposure. Similarly, novel adverse events and events involving new SCs are more likely to be reported or published in the medical literature.
The consumption of cannabis affects the cardiovascular system and increases the risk of myocardial infarction. 78, 79 Similarly, cannabis has been implicated in ischemic stroke, especially multifocal intracranial stenosis among young adults. 80 The potential mechanisms include cardiac ischemia due to increased heart rate, postural hypotension, impaired oxygen supply arising from raised carboxyhemoglobin levels, especially in conjunction with tobacco smoking, and catecholaminemediated pro-arrhythmic effects. 81 It is thus perhaps unsurprising that similar adverse outcomes have occurred following the use of SCs given their increased potency at CB 1 receptors. Whether these compounds have significant direct effects on other receptors is still unknown.
The comparatively short period for which SC have been available and used in the general community means that long-term outcomes are currently unknown. However, the occurrence of acute kidney injury has implications for future health with a meta-analysis estimating a nearly ninefold increase in the risk of developing chronic kidney disease, and a three-fold increase in the risk for end stage renal disease, compared to those who have not had AKI. 82 Thus, even low prevalence events with apparently limited duration, like AKI, have the potential to result in significant health costs following the resolution of acute symptoms. The other effects with long-term potential health consequences are initiation or exacerbation of psychiatric disorders, particularly psychosis. These are extremely debilitating and disabling conditions with large societal and health impacts for patients, families and the health system.
Clinical Implications
Synthetic cannabinoid intoxication appears to be a distinct and novel clinical entity. Use of SCs can cause more significant clinical effects than marijuana. There also appear to be qualitative differences in the nature of the symptoms with which patients present. The sheer number of SCs available and the rate at which they continue to change confound examinations of the scale and extent of the problem. 83 More recent formulations (in the UK termed 'Third Generation') are typically more potent that earlier SCs and seem to be associated with greater harms. 84 Trecki and colleagues report that the incidence of clusters and severity of adverse events involving SCs appears to be increasing. 85 This increase could be due to greater familiarity with presentations, better coordination between public health authorities and laboratories or the characteristics of newer SCs. 85 The overall effects of SC can resemble those of cannabis, but other than anxiety and paranoia these are not usually the symptoms associated with acute hospital presentation. Instead, patients seem to present in EDs because of behavioural abnormalities (agitated behaviour, psychosis, anxiety) or symptoms associated with acute critical illness. The latter includes seizures (which if prolonged can lead to rhabdomyolysis and hyperthermia), AKI, myocardial ischaemia and infarction in demographic groups where this would be most unusual. The majority of mild intoxications only require symptomatic treatment and generally do not require hospital admission. Severe intoxications, involving seizures, severe agitation or mental health disturbances, arrhythmias and significant chest pain, should be admitted to hospital for further investigation.
The lack of an antidote to SCs, analogous to that for opioid overdose, complicates management, as does the unpredictable effects and lack of a clear toxidrome to distinguish SCs from other recreational drugs. 85 The differential diagnosis requires the elimination of diverse conditions including hypoglycemia, CNS infection, thyroid hyperactivity, head trauma and mental illness. 86 Benzodiazepines are usually sufficient to control agitation: while the use of haloperidol has also been described, 86 caution is advised in undifferentiated agitation. Benzodiazepine failure should prompt consideration of definitive airway control. In addition to intravenous fluids for dehydration, the primary goals are protecting the airway, preventing rhabdomyolysis and to monitor for either cardiac or cerebral ischemia. 
Conclusions
Data from poison centers and drug monitoring systems in Europe, the UK, the US, and Australia illustrate trends of increased use of SCs. The number of unique SCs appears to continue growing, but the SCs seem to share common characteristics within the class. The most common effects include tachycardia, agitation, and nausea; these generally respond to supportive care. However, physicians should be aware of the severe cardiovascular, cerebrovascular, neurological, psychiatric, and renal effects, which occur in a minority of cases.
Differences among compounds in the class are difficult to assess. Methods to detect, identify, and confirm new SCs lag behind the appearance of these drugs. Further, many of the cases depend upon self-report of the patients, whose information may be unreliable or inaccurate. Improving the availability of advanced laboratory resources will improve our ability to recognize SCs with higher risk of severe toxicity. 
